ArticleBlood cancer journal2020

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis.

Meletios A Dimopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.